Learn how our experience and differentiated science is enabling us to design and develop a scalable CAR T 2.0 product for autoimmune disease that could potentially eliminate or reduce lymphodepletion to meet the unique needs of patients. #CART #celltherapy #immunotherapy Uncover the Potential of ALLO-329: Allogene.com/Pipeline
Allogene Therapeutics
Biotechnology
South San Francisco, California 65,843 followers
Über uns
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
- Website
-
www.allogene.com
External link for Allogene Therapeutics
- Industrie
- Biotechnology
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- South San Francisco, California
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2017
- Spezialitäten
- oncology, cancer, biotechnology, immunotherapy, CAR T, and autoimmune
Standorte
-
Primäre
Wegbeschreibung erhalten
210 E Grand Ave
South San Francisco, California 94080, US
-
Wegbeschreibung erhalten
7400 Gateway Blvd
Newark, California 94560, US
Employees at Allogene Therapeutics
Aktualisierungen
-
Join us August 23 in South San Francisco to learn about Allogene and our mission to bring investigational “off-the-shelf” #CART products to patients with cancer and autoimmune disease.
“I felt the speaker gave a comprehensive overview of their company and what they are trying to accomplish. I really enjoyed the talk, and am looking forward to the second series." - Survey response from July 26 event attendee The second installment of our four-part biotech speaker series co-sponsored by Biocom California takes place August 23. Come join us to hear about what’s happening east of 101 according to Allogene Therapeutics. Register here: https://lnkd.in/gVBBNpk9 . Free childcare for children 2.5 years old and potty-trained! #biotech #southsanfrancisco #freeevent #lifesciences #biotechnology #speakerseries #allogene
-
-
Watch the latest DataBrief where Dr. Zachary Roberts, our Head of R&D and Chief Medical Officer, talks about the potential of our investigational AlloCAR T™ product cema-cel to become the first #CART treatment available as part of frontline therapy. #celltherapy #immunotherapy Watch DataBrief: https://lnkd.in/gyfMGiNJ
-
We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline
-
Join us August 13 at 10:00 am EST for the Canaccord Genuity Global Growth Conference where our CEO David Chang will share Allogene's plans to redefine the future of CAR T. #CART #celltherapy #immunotherapy Listen here: https://lnkd.in/eBV4zW9
-
-
We are looking forward to participating in the upcoming Canaccord Genuity Group Inc. and Baird investor conferences. Tune into our fireside chats to hear why we believe in the future of AlloCAR T™ products. Webcasts available in the investor section of our website. #CART #celltherapy #immunotherapy https://bit.ly/4dD8Ehh
-
Pleased to report our Q2 2024 corporate update and business highlights. https://bit.ly/3LXuK27
-
We are delighted to congratulate Allogene Board Member Liz Barrett on being recognized by Forbes as one of the ‘50 Over 50’ for Innovation. A well-deserved recognition for a leader who continues to pave the way for women in biotech. #ForbesOver50.
The members of the #ForbesOver50 manage billions of dollars of investments, conduct world-class orchestras and consistently break athletic records. But where did they get their start? We asked, and they answered. https://lnkd.in/eFN_2c_Y Mika Brzezinski, Know Your Value
-
-
At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that do what autologous CAR T therapies cannot. #CART #celltherapy #immunotherapy Discover the Allogeneic Advantage: Allogene.com/Home
-
Ähnliche Seiten
Finanzierung
Allogene Therapeutics
5 total rounds
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 110.0M